Meta-Flux has built an AI-driven decision-support platform that acts as a virtual biologist, integrating gene, protein, and metabolic pathway data to show how biological systems function as a whole. Researchers use the system to test hypotheses, pick the most promising therapeutic pathways, and make quicker go/no-go calls, cutting costs and reducing late-stage trial failures. By converting complex datasets into clear, actionable insights, the software helps drug developers avoid costly dead ends and match compounds to the right disease subtypes and patient populations. The company positions itself as a biology-first AI partner for pharmaceutical firms, aiming to shorten the path from discovery to clinical application. Meta-Flux recently completed Techstars Chicago (powered by J.P. Morgan), MassBio DRIVE in Boston, and the NDRC Accelerator at Dogpatch Labs in Dublin, gaining industry mentors and early traction. With fresh capital, the startup is expanding its team to support collaborations across Europe and the United States. No revenue or user metrics have been disclosed.

Total raised

$2M

Funding rounds

1

Latest round

Seed

Latest activity

Oct 2025